Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1992 Mar;60(3):1150–1155. doi: 10.1128/iai.60.3.1150-1155.1992

Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.

I Marsili 1, M Pizza 1, F Giovannoni 1, G Volpini 1, M Bartalini 1, R Olivieri 1, R Rappuoli 1, L Nencioni 1
PMCID: PMC257606  PMID: 1541530

Abstract

Bordetella pertussis 165-9K/129G, which produces a nontoxic form of pertussis toxin (PT), was used to prepare a whole-cell diphtheria-tetanus-pertussis (DTP) vaccine. The in vivo potency and the serological response induced by this vaccine were comparable to those of the conventional DTP vaccine which contains active PT. The toxic activities induced by PT such as leukocytosis, histamine sensitivity, and potentiation of anaphylactic reactions, which are present in the conventional DTP vaccine, were absent in the new vaccine. These results suggest that the introduction of a whole-cell vaccine containing B. pertussis 165-9K/129G would induce the same immunity as the conventional vaccine and would avoid the administration of a harmful toxin to children.

Full text

PDF
1150

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black W. J., Munoz J. J., Peacock M. G., Schad P. A., Cowell J. L., Burchall J. J., Lim M., Kent A., Steinman L., Falkow S. ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis. Science. 1988 Apr 29;240(4852):656–659. doi: 10.1126/science.2896387. [DOI] [PubMed] [Google Scholar]
  2. Cherry J. D. 'Pertussis vaccine encephalopathy': it is time to recognize it as the myth that it is. JAMA. 1990 Mar 23;263(12):1679–1680. [PubMed] [Google Scholar]
  3. Engvall E., Perlmann P. Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol. 1972 Jul;109(1):129–135. [PubMed] [Google Scholar]
  4. Gillenius P., Jätmaa E., Askelöf P., Granström M., Tiru M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J Biol Stand. 1985 Jan;13(1):61–66. doi: 10.1016/s0092-1157(85)80034-2. [DOI] [PubMed] [Google Scholar]
  5. Griffin M. R., Ray W. A., Mortimer E. A., Fenichel G. M., Schaffner W. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. JAMA. 1990 Mar 23;263(12):1641–1645. [PubMed] [Google Scholar]
  6. Hewlett E. L., Sauer K. T., Myers G. A., Cowell J. L., Guerrant R. L. Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin. Infect Immun. 1983 Jun;40(3):1198–1203. doi: 10.1128/iai.40.3.1198-1203.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kume K., Nakai T., Samejima Y., Sugimoto C. Properties of dermonecrotic toxin prepared from sonic extracts Bordetella bronchiseptica. Infect Immun. 1986 May;52(2):370–377. doi: 10.1128/iai.52.2.370-377.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Miller D. L., Ross E. M., Alderslade R., Bellman M. H., Rawson N. S. Pertussis immunisation and serious acute neurological illness in children. Br Med J (Clin Res Ed) 1981 May 16;282(6276):1595–1599. doi: 10.1136/bmj.282.6276.1595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Miyamura K., Nishio S., Ito A., Murata R., Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration. J Biol Stand. 1974 Jul;2(3):189–201. doi: 10.1016/0092-1157(74)90015-8. [DOI] [PubMed] [Google Scholar]
  10. Munoz J. J., Arai H., Bergman R. K., Sadowski P. L. Biological activities of crystalline pertussigen from Bordetella pertussis. Infect Immun. 1981 Sep;33(3):820–826. doi: 10.1128/iai.33.3.820-826.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Munoz J. J., Peacock M. G. Action of pertussigen (pertussis toxin) on serum IgE and on Fc epsilon receptors on lymphocytes. Cell Immunol. 1990 May;127(2):327–336. doi: 10.1016/0008-8749(90)90136-f. [DOI] [PubMed] [Google Scholar]
  12. Munoz J. J., Peacock M. G. Role of pertussigen (pertussis toxin) on the mouse protective activity of vaccines made from Bordetella species. Microbiol Immunol. 1989;33(4):341–355. doi: 10.1111/j.1348-0421.1989.tb01982.x. [DOI] [PubMed] [Google Scholar]
  13. Munoz J. J., Sewell W. A. Effect of pertussigen on inflammation caused by Freund adjuvant. Infect Immun. 1984 Jun;44(3):637–641. doi: 10.1128/iai.44.3.637-641.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nencioni L., Pizza M., Bugnoli M., De Magistris T., Di Tommaso A., Giovannoni F., Manetti R., Marsili I., Matteucci G., Nucci D. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect Immun. 1990 May;58(5):1308–1315. doi: 10.1128/iai.58.5.1308-1315.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pizza M., Covacci A., Bartoloni A., Perugini M., Nencioni L., De Magistris M. T., Villa L., Nucci D., Manetti R., Bugnoli M. Mutants of pertussis toxin suitable for vaccine development. Science. 1989 Oct 27;246(4929):497–500. doi: 10.1126/science.2683073. [DOI] [PubMed] [Google Scholar]
  16. Podda A., Nencioni L., De Magistris M. T., Di Tommaso A., Bossù P., Nuti S., Pileri P., Peppoloni S., Bugnoli M., Ruggiero P. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. J Exp Med. 1990 Sep 1;172(3):861–868. doi: 10.1084/jem.172.3.861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Podda A., Nencioni L., Marsili I., Peppoloni S., Volpini G., Donati D., Di Tommaso A., De Magistris M. T., Rappuoli R. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa. Vaccine. 1991 Oct;9(10):741–745. doi: 10.1016/0264-410x(91)90290-m. [DOI] [PubMed] [Google Scholar]
  18. Sato H., Ito A., Chiba J., Sato Y. Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect Immun. 1984 Nov;46(2):422–428. doi: 10.1128/iai.46.2.422-428.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sato Y., Cowell J. L., Sato H., Burstyn D. G., Manclark C. R. Separation and purification of the hemagglutinins from Bordetella pertussis. Infect Immun. 1983 Jul;41(1):313–320. doi: 10.1128/iai.41.1.313-320.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Stainer D. W., Scholte M. J. A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol. 1970 Oct;63(2):211–220. doi: 10.1099/00221287-63-2-211. [DOI] [PubMed] [Google Scholar]
  21. Steinman L., Weiss A., Adelman N., Lim M., Zuniga R., Oehlert J., Hewlett E., Falkow S. Pertussis toxin is required for pertussis vaccine encephalopathy. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8733–8736. doi: 10.1073/pnas.82.24.8733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stewart G. T., Wilson J. Pertussis vaccine and serious acute neurological illness in children. Br Med J (Clin Res Ed) 1981 Jun 13;282(6280):1968–1969. doi: 10.1136/bmj.282.6280.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Storsaeter J., Olin P., Renemar B., Lagergård T., Norberg R., Romanus V., Tiru M. Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. Pediatr Infect Dis J. 1988 Sep;7(9):637–645. doi: 10.1097/00006454-198809000-00008. [DOI] [PubMed] [Google Scholar]
  24. Worcester J., Wilson E. B. A Table Determining L.D.50 or the Fifty Per Cent End-Point. Proc Natl Acad Sci U S A. 1943 Jul;29(7):207–212. doi: 10.1073/pnas.29.7.207. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES